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Objective: Effects of daclizumab and antithymocyte globulin induction on acute
rejection, bronchiolitis obliterans syndrome, and survival after lung transplantation
are unknown. We hypothesized that daclizumab results in less acute rejection and
bronchiolitis obliterans and better survival than antithymocyte globulin.
Methods: Consecutive adult lung transplants (n 5 163) at the University of Virginia
from January 1998 to May 2006 were reviewed. Antithymocyte globulin induction
was routinely performed before January 2002 (65 patients), after which all patients
received daclizumab (98 patients). Estimates of cumulative event rate of acute rejec-
tion, bronchiolitis obliterans, and death were calculated by Kaplan–Meier method and
between-group differences compared by log-rank test. Cox proportional hazards
models were fitted to assess treatment effects adjusted for covariates.
Results: Groups were similar in demographics and preoperative and intraoperative
risk factors. Maintenance immunosuppression changed during the study, and myco-
phenolate mofetil was more commonly given to patients receiving daclizumab. By
Kaplan–Meier method, daclizumab was associated with significantly less acute rejec-
tion (P5 .002), less bronchiolitis obliterans (P5 .02), and improved overall survival
(P 5 .04). Induction agent was highly associated with acute rejection (P 5 .002),
bronchiolitis obliterans (P 5 .02), and mortality (P 5 .05); antimetabolite agent
was associated only with acute rejection (P5 .01). Adjusting for covariates, induction
agent remained significantly predictive for acute rejection (P5 .02) and bronchiolitis
obliterans (P 5 .05), approaching significance for survival (P 5 .07).
Conclusion: Lung transplant recipients receiving daclizumab for induction had signif-
icantly less acute rejection and bronchiolitis obliterans than those receiving antithy-
mocyte globulin, with possibly improved survival. Improvements in acute rejection
may have been confounded by the use of mycophenolate mofetil.
L
ung transplantation for progressive end-stage pulmonary failure is the pre-
ferred treatment for appropriately selected surgical patients. Outcomes after
lung transplantation are limited by acute rejection (AR) and particularly by
chronic rejection, manifested as bronchiolitis obliterans syndrome (BOS).1 According
to data from the International Society for Heart and Lung Transplantation (ISHLT),
AR affects more than 50% of recipients in the first year after transplantation.2 Centers
with aggressive screening programs have found pathologic evidence of AR in 85% of
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ETAbbreviations and Acronyms
AR 5 acute rejection
AT 5 antithymocyte globulin
BOS 5 bronchiolitis obliterans syndrome
CMV 5 cytomegalovirus
HR 5 hazard ratio
IL-2R 5 interleukin 2 receptor
ISHLT 5 International Society for Heart and Lung
Transplantation
MMF 5 mycophenolate mofetil
PTLD 5 posttransplantation lymphoproliferative disorder
patients.3 It is well documented that AR is a significant risk
factor for the development of BOS.4-5 BOS has been found
in 45% of patients by 5 years after lung transplantation and
is the most common cause (30%) of late death.2 Induction
agents have been shown to decrease the number of patients
requiring treatment for AR. Routine use of a specific induc-
tion regimen has not been universally accepted, however,
with approximately 50% of patients receiving no induction
immunosuppression.2 The two most common induction strat-
egies are daclizumab (Zenapax), a monoclonal IgG antibody
to interleukin 2 receptor (IL-2R), and antithymocyte globulin
(AT), a polyclonal horse antibody to human thymus (primar-
ily T lymphocytes). There remains considerable debate re-
garding which regimen is optimal for preventing AR.6-9
Moreover, no study has evaluated long-term outcomes of
BOS and survival with different induction regimens. The
purpose of this study was to examine the effects of daclizu-
mab induction and AT induction on the incidences of AR
and BOS and on survival.
Methods
Patient Population
Data from patients undergoing lung transplantation are entered con-
currently into the University of Virginia Lung Transplant Registry.
Follow-up events are entered by our transplant coordinators as they
occur. A retrospective review of 163 consecutive patients undergo-
ing transplantation from January 1998 to September 2006 was per-
formed, as approved by the University of Virginia Institutional
Review Board (IRB 12006). All patients had complete data and fol-
low-up. Standard single- or double-lung transplantation procedures
were performed. Cardiopulmonary bypass was used selectively.
All transplant recipients received azathioprine (2.5 mg/kg) and
methylprednisolone (1 g) before organ implantation. From 1998
to 2002, all patients (n5 65) underwent induction immunosuppres-
sion consisting of methylprednisolone (250 mg every 8 hours for
three doses) and AT (15 mg/kg on day 1, 10 mg/kg on day 2, and
7.5 mg/kg on days 3–7; Pharmacia Corp, Kalamazoo, Mich). AT
was stopped for hypersensitivity, leukopenia, or thrombocytopenia.
Daily triple maintenance immunosuppression included cyclosporine
(INN ciclosporin) or tacrolimus (serum trough goal of 10–15 ng/
mL), azathioprine (2 mg/kg) or mycophenolate mofetil (MMF, 2 g),The Journal of Thorand prednisone (20 mg). Beginning in January 2002, all patients
(n 5 98) received induction with methylprednisolone (as before)
and daclizumab (Zenapax, 1 mg/kg on day of surgery, then every
2 weeks for a total of five doses; Hoffmann-LaRoche Inc, Nutley,
NJ). Daily maintenance immunosuppression included cyclosporine
or tacrolimus, MMF (2 g), and prednisone (20 mg). Patients re-
ceived cytomegalovirus (CMV) prophylaxis during the study period
with ganciclovir sodium (INN ganciclovir, 3 mg/ kg twice daily) or
valganciclovir hydrochloride (INN valganciclovir, Valcyte, 900 mg
daily; Hoffmann-LaRoche) from day 7 through day 21. After com-
pletion of ganciclovir sodium, CMV prophylaxis was maintained
with acyclovir (INN aciclovir, 800 mg four times daily). When
the donor was positive for CMV and the recipient was negative
for CMV, ganciclovir was continued until day 90 and CMV intrave-
nous immune globulin (Cytogam; Genesis Bio-Pharmaceuticals,
Hackensack, NJ) was administered (150 mg/kg on day 4 and at
weeks 2, 4, 6, and 8, then 100 mg/kg at weeks 12 and 16).
The database contained donor age; recipient characteristics in-
cluding age, sex, ethnicity, body mass index, diagnosis, and CMV
status; operative events including single- versus double-lung trans-
plantation, use of cardiopulmonary bypass, and graft ischemic time;
and postoperative variables including oxygenation index, AR, BOS,
and survival status. The variable of CMV mismatch was defined as
differing donor and recipient CMV statuses. Graft ischemic time for
double lung-transplantation was entered into the model as an aver-
age of the ischemic time for both lungs. Maintenance immunosup-
pression regimen was entered into the registry. Outcomes evaluated
included AR, BOS, and mortality.
Definitions of AR and BOS
AR was defined by a panel of pulmonologists, thoracic surgeons,
and pathologists and was agreed on by protocol; this definition
did not change during the study period. Diagnosis was made accord-
ing to either clinical or pathologic criteria. Clinical criteria included
an acute change in symptoms, a new radiographic infiltrate, or a de-
crease in forced expiratory volume in 1 second of 20% from base-
line not explained by infection or other cause. Lung biopsy was
conducted if clinical criteria failed to diagnose AR. Pathologic diag-
nosis of rejection was defined by ISHLT grade A3 or higher histo-
logic grade.10 Treatment included corticosteroids or augmentation
of immunosuppression. BOS was determined by a decrease in pul-
monary function testing greater than 20% from baseline (current
forced expiratory volume in 1 second divided by two highest con-
secutive postoperative values). Follow-up data were used to derive
comparisons between immunosuppression regimens with respect to
the incidences of AR and BOS and to survival.
Statistical Analysis
Bivariate analyses between groups and categoric variables were
done by either c2 test or Fisher exact test as appropriate. The 2-
sample t test or Wilcoxon rank sum test was used to compare con-
tinuous variables. For comparing time to first episode of AR, time
to first episode of BOS, and survival, the Kaplan–Meier method
was used, and differences between groups were compared by log-
rank test. Because median follow-up was 1.8 years in the daclizu-
mab group, AR, BOS, and survival were compared with the c2
test at 2 years after transplantation. The Kaplan–Meier model did
not account for repeated episodes of AR for a given patient or foracic and Cardiovascular Surgery c Volume 135, Number 3 595
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ETTABLE 1. Patient demographics, diagnosis, and intraoperative factors in patients receiving daclizumab or antithymocyte
globulin induction
Variable Daclizumab (n 5 98)
Antithymocyte globulin
(n 5 65) P value*
Donor age (y, median and range) 31.6 (9–63) 29.6 (14–61) .38
Recipient factors
Recipient age (y, median and range) 52.7 (21–68) 53.9 (25–69) .52
Female (No.) 43 (44%) 35 (54%) .21
African American (No.) 14 (14%) 6 (9%) .33
Body mass index (kg/m2, median and range) 24.4 (16–32) 25.2 (15–34) .26
Cytomegalovirus mismatch (No.) 40 (40%) 24 (37%) .62
Recipient diagnosis (No.) .20
Chronic obstructive pulmonary disease 59 (60%) 38 (58%)
Idiopathic pulmonary fibrosis 12 (12%) 15 (23%)
Sarcoidosis 10 (10%) 6 (9%)
Cystic fibrosis 13 (13.3%) 1 (1.5%)
Bronchiectasis 1 (1.0%) 3 (4.6%)
Lymphangioleiomyomatosis 1 (1.0%) 0 (0%)
Primary pulmonary hypertension 1 (1.0%) 1 (1.5%)
Eisenmenger syndrome 0 (0%) 1 (1.5%)
Operative factors
Oxygenation index (median and range) 5.6 (1.1–28.9) 4.6 (1.1–21.2) .30
Graft ischemic time (min, median and range) 295.7 (110–549) 248 (80–528) ,.0001y
Need for CPB (No.) 18 (18.4%) 7 (10.8%) .27
CPB time (min, median and range) 171.1 (54–323) 204.2 (117–246) .27
Need for ECMO 3 (3.1%) 4 (6.2%) .44
Double-lung transplant 26 (26.5%) 8 (12.3%) .03y
CPB, Cardiopulmonary bypass; ECMO, extracorporeal membrane oxygenation. *P values were determined with t tests. ySignificant difference.progression of BOS. Cox proportional hazards models were fitted to
investigate the effect of induction on AR, BOS, and survival, with
adjustment for the covariates of donor age, recipient age, CMV
mismatch, and diagnosis. All analyses were performed with SAS
version 9.1.3 software (SAS Institute, Inc, Cary, NC).
Results
Sixty-five patients underwent AT induction (median follow-
up 4.6 years), and 98 patients underwent daclizumab induc-
tion (median follow-up 1.8 years). Recipient characteristics,
diagnoses, and operative factors are presented in Table 1.
No differences in donor age, recipient age, ethnicity, body
mass index, or CMV mismatch were identified. More than
half of the transplant recipients undergoing AT induction
were women, which was not significantly different from
the daclizumab group. Diagnoses were similar between in-
duction treatment groups. Graft ischemic times were signifi-
cantly longer in the daclizumab group (mean6 SE 2956 8.1
minutes) than in the AT group (226.3 6 10.6 minutes, P 5
.001). The number of patients undergoing double-lung trans-
plantation significantly increased during the study period,
from 12.3% (8/65) during the AT era to 26.5% (26/98) in
the daclizumab era (P 5 .03). Importantly, among patients
receiving AT, the median number of doses of the induction
agent tolerated was four. Among the 65 patients in the AT596 The Journal of Thoracic and Cardiovascular Surgery c Magroup, a total of 61 patients (94%) tolerated two doses of
AT and 43 patients (66%) completed four doses of AT. In
fact, only 2 patients (3%) were able to tolerate a complete
7-day course per our induction protocol. AT was discontin-
ued because of severe hypersensitivity reactions, leukopenia,
thrombocytopenia, or evidence of infection.
Initial maintenance immunosuppression in the AT group
varied during this study period as a result of the introductions
of MMF and tacrolimus (Table 2). In the AT group, 11 pa-
tients received cyclosporine, whereas 53 patients received
tacrolimus. In this same group, 5 patients received MMF, and
58 patients were treated with azathioprine. The daclizumab
TABLE 2. Maintenance immunosuppression during the
study period
Maintenance agent 1998-2002* 2002-2006y
Interleukin 2 inhibitor
Cyclosporine 11 5
Tacrolimus 53 93
Antimetabolite
Azathioprine 58 5
Mycophenolate mofetil 5 93
*Induction agent in period from 1998 to 2002 was antithymocyte globulin.
yInduction agent in period from 2002 to 2006 was daclizumab.rch 2008
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Figure 1. A, Kaplan–Meier probability curve comparing incidences of acute rejection after daclizumab and antith-
ymocyte globulin (ATGAM) induction. B, Kaplan–Meier probability curve comparing incidences of BOS after dacli-
zumab and antithymocyte globulin (ATGAM) induction. C, Kaplan–Meier survival curves for lung transplantation
after daclizumab and antithymocyte globulin (ATGAM) induction.group received mainly tacrolimus (93 patients) rather than
cyclosporine (5 patients) and MMF (93 patients) rather
than azathioprine (5 patients).
According to the Kaplan–Meier method, AR occurred less
frequently among patients receiving daclizumab than among
those undergoing AT induction (P 5 .002; Figure 1, A). AR
tended to occur in the first 3 to 6 months after transplantation,
irrespective of induction regimen. Beyond 6 months, the
Kaplan–Meier estimator curves are parallel, regardless of in-
duction regimen. At 2 years after transplantation, patients re-
ceiving daclizumab had less AR (9%, 9/98) than did patients
receiving AT (28%, 18/65, P 5 .002). The time to the firstThe Journal of Thoraepisode of BOS was significantly shorter among patients
undergoing AT induction than among those undergoing da-
clizumab induction (P 5 .02; Figure 1, B). In the group re-
ceiving daclizumab, BOS rarely occurred until 2 years after
transplantation, whereas AT induction patients had BOS
develop as early as 1 year after transplantation. The two
curves have different slopes, suggesting less BOS with
time after daclizumab induction. At 2 years after transplanta-
tion, BOS was less common among patients who received
daclizumab (6.4%, 6/96) than among those who received
AT (23%, 14/60, P 5 .002). Furthermore, daclizumab
induction demonstrated improved survival relative to ATcic and Cardiovascular Surgery c Volume 135, Number 3 597
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ETinduction (P 5 .04; Figure 1, C). At 2-year follow-up,
survival in the daclizumab group was 94%, compared with
83% survival in the AT group (P 5 .03).
Bivariate analyses were performed to identify variables
influencing the three outcomes (Table 3). AR was strongly
associated with induction regimen (P5 .002) and antimetab-
olite maintenance drug (P 5 .01). Calcineurin inhibitor was
not significantly associated with AR. BOS was associated
with induction,(P5 .02) but not with other variables, includ-
ing maintenance immunosuppression. Mortality was signifi-
cantly associated only with induction (P5 .05) and not with
recipient or donor age, body mass index, diagnosis, CMV
mismatch, or maintenance immunosuppression.
A Cox proportional hazards model was fitted to adjust for
other covariates. Induction agent was the only variable asso-
ciated with all three outcomes. Antimetabolite was associ-
ated only with AR. Because of a high correlation between
antimetabolite agent and induction agent (Table 2), both var-
iables could not be added to the model; this would have
resulted in a statistically invalid model. In an attempt to dis-
tinguish the confounding effects of antimetabolite mainte-
nance immunosuppression on AR, analysis of maintenance
immunosuppression within each induction group was per-
formed. Among patients who received AT induction, AR de-
veloped in 20% of patients receiving MMF (1/5) and 31% of
patients receiving azathioprine (18/40, P 5 .60). Among
patients receiving daclizumab induction, AR developed in
9% of patients receiving MMF immunosuppression (9/93)
and in 0% of those receiving azathioprine (0/5, P 5 .46).
Other clinically significant variables of induction regimen,
donor age, recipient age, CMV mismatch, and diagnosis
were included in the model (Table 4). Type of induction reg-
TABLE 3. Bivariate (univariate) analysis of acute rejection,
bronchiolitis obliterans syndrome, and mortality
P values*
Variable
Acute
rejection
Bronchiolitis
obliterans Death
Donor age .67 .98 .89
Recipient age .28 .61 .71
Induction agent .002y .02y .05y
Maintenance
immunosuppression
Mycophenolate mofetil vs
azathioprine
.01y .09 .07
Tacrolimus vs
cyclosporine
.40 .09 .53
Double-lung transplant .10 .86 .77
Ethnicity .76 .12 .65
Sex .06 .90 .97
Body mass index .27 .42 .81
Diagnosis .40 .84 .60
Cytomegalovirus mismatch .18 .89 ..99
*P values from Cox proportional hazards models. ySignificant difference.598 The Journal of Thoracic and Cardiovascular Surgery c Maimen was significantly associated with AR, with a hazard
ratio (HR) of 2.71 (P5 .02). Interestingly, younger recipient
age was weakly but significantly associated with AR (HR
0.94, P 5 .03).
Specific induction regimen was significantly associated
with the onset of BOS (HR 2.12, P 5 .05), with AT being
associated with the onset of BOS. Furthermore, AT induction
approached a significant correlation with mortality (HR 2.31,
P 5 .07). No other variable, including diagnosis, was
TABLE 4. Multivariate analyses (Cox proportional hazards
models) for acute rejection, bronchiolitis obliterans
syndrome, and mortality
Variable
Hazard
ratio
95% Confidence
interval
P
value
Acute rejection
Induction
(antithymocyte globulin vs
daclizumab)
2.71 1.15–6.39 .02*
Donor age (per y) 1.00 0.98–1.04 .73
Recipient age (per y) 0.94 0.90–0.99 .03*
CMV mismatch (vs CMV
match)
1.78 0.79–4.03 .17
Diagnosis (vs COPD)
Idiopathic pulmonary
fibrosis
0.75 0.25–2.27 .60
Sarcoid 0.19 0.02–1.59 .12
Othery 0.14 0.02–0.91 .04*
Bronchiolitis obliterans syndrome
Induction (antithymocyte
globulin vs daclizumab)
2.12 0.99–4.49 .05*
Donor age (per y) 1.00 0.98–1.02 .95
Recipient age (per y) 0.97 0.94–1.01 .18
CMV mismatch (vs CMV
match)
1.64 0.81–3.32 .17
Diagnosis (vs COPD)
Idiopathic pulmonary
fibrosis
1.08 0.48–2.44 .86
Sarcoid 1.85 0.55–6.20 .31
Othery 0.42 0.12–1.50 .18
Death
Induction (antithymocyte
globulin vs daclizumab)
2.31 0.92–5.78 .07
Donor age (per y) 1.00 0.97–1.03 .98
Recipient age (per y) 1.00 0.96–1.04 .89
CMV mismatch (vs CMV
match)
1.43 0.68–2.98 .35
Diagnosis (vs COPD)
Idiopathic pulmonary
fibrosis
1.48 0.65–3.38 .35
Sarcoid 2.78 0.86–8.98 .08
Othery 1.03 0.29–3.67 .99
CMV, Cytomegalovirus; COPD, chronic obstructive pulmonary disease. *Sig-
nificant difference. yOther diagnoses were cystic fibrosis, bronchiectasis,
primary pulmonary hypertension, Eisenmenger syndrome, and lymphangio-
leiomyomatosis.rch 2008
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other covariates.
From our analyses, AR was correlated with BOS, and
BOS was correlated with mortality. During the study period,
46% of patients with AR (13/28) had BOS develop, com-
pared with 26% of patients who did not have an episode of
AR (35/135) who had BOS develop (P 5 .04). Similarly,
42% of patients with BOS died during the study period, com-
pared with 18% of patients who died without any antecedent
BOS (21/115, P 5 .002).
The incidence of malignancy and posttransplantation lym-
phoproliferative disorder (PTLD) was not different between
the two induction groups. Five patients in the AT group
(7.7%) and 3 patients in the daclizumab group (3.1%) had
malignancy develop during follow-up (P 5 .26). Only 1 pa-
tient in the daclizumab group and no patients in the AT group
had PTLD develop.
Discussion
This study examined the effects of daclizumab and AT induc-
tion on the incidence of AR and BOS and on survival in 163
consecutive lung transplant recipients at a single institution.
January 2002 marked the point at which the routine induction
agent changed from AT to daclizumab for all patients at our
institution. Despite relatively similar demographic data in
the patient groups, patients receiving daclizumab induction
demonstrated less AR and less BOS, with a trend toward im-
proved survival relative to AT induction. Only 3% of patients
were able to tolerate the full AT induction, whereas all pa-
tients tolerated induction with daclizumab. With so few pa-
tients in the AT group completing induction, patients were
stratified by an intention-to-treat analysis by induction agent,
rather than by a dichotomous variable of completion of induc-
tion versus incomplete induction.
The rationale for induction therapy for organ transplanta-
tion is to suppress the initial host immune response to the
allograft. This strategy has been shown to decrease the inci-
dence of AR in kidney and combined kidney–pancreas trans-
plantation.11-12 In lung transplantation, longitudinal studies
indicate that AR primarily occurs within 4 months after trans-
plantation and decreases with time.13 Despite the rationale for
induction therapy, according to ISHLT data, more than 50%
of lung transplant recipients do not receive any induction
agent.2
Specifically, IL-2R antagonists have been shown to affect
the development of AR. In kidney as well as heart transplant
recipients, induction immunosuppression with daclizumab,
a potent IL-2R monoclonal antibody, has been associated
with a decrease in the number of episodes of AR.14-15 The ef-
ficacy of daclizumab as an induction agent in preventing AR
after lung transplant has been studied.6-9 Garrity and col-
leagues6 demonstrated that the incidence of grade 2 AR sig-
nificantly decreased from 48% without induction to 18% with
daclizumab during the first 6 months after transplantation.The Journal of ThorFew studies have compared daclizumab with AT as induction
immunosuppression for lung transplantation. In a prospective
trial, Brock and associates7 demonstrated no differences in
AR, BOS, or survival among three induction regimens
(OKT3, AT, and daclizumab). Despite a relatively small sam-
ple size in each group (total of 87 patients divided into three
groups), however, patients receiving daclizumab had signif-
icantly fewer infections than did those receiving the other
two induction agents. Burton and colleagues8 analyzed
over more than lung transplant recipients and documented
less AR with AT induction than with daclizumab. In that
study, 100% of patients receiving daclizumab induction
had AR by 2 years after transplantation, a rate notably higher
than in any other study, and outcomes of BOS and mortality
were not reported. In a recent report of 25 patients, daclizu-
mab was associated with significantly improved freedom
from AR relative to AT.9
Although the effects of induction therapy on AR have
been documented, outcomes of BOS and survival have not
been well described. Only one previous study attempted to
find any differences between daclizumab and AT induction
with respect to BOS or survival. This small study (25
patients) did not find significant differences. Larger studies
comparing the two induction agents have not evaluated
BOS or survival. AR is the most important risk factor for
the development of BOS.4,5 BOS is the most common cause
of death after lung transplantation.2 In our report, AR was
significantly associated with the development of BOS, and
BOS in turn was significantly associated with mortality dur-
ing the study period. Our investigation supports the concept
that AR, BOS, and survival are related outcomes.
Despite conflicting data regarding daclizumab versus AT
induction, the ISHLT Registry has noted increasing use of
IL-2R antibody induction rather than AT.2 In fact, daclizu-
mab induction is used for more than 30% of lung transplant
recipients, whereas AT induction has declined to approxi-
mately 10%.2 There are several explanations for the increased
use of daclizumab. First, AT is not well tolerated, as seen in
our study, with a minority of patients in the AT group com-
pleting our induction protocol because of significant adverse
effects. Second, patients receiving AT induction demonstrate
higher infection rates than are seen with daclizumab induc-
tion.7 In a study of heart transplant recipients, bacterial infec-
tions were three times more likely after AT induction than
after daclizumab induction.16 Brock and associates7 reported
that viral infections were three times more common after AT
induction than after daclizumab induction. Finally, the risk
profile of daclizumab is low, and the agent appears to be
well tolerated. In our study, no patient required the discontin-
uation of daclizumab because of an adverse effect.
According to bivariate analysis, only induction agent was
a significant predictor for all three outcomes. Importantly, an-
timetabolite maintenance agent was associated with the out-
come of AR but not with BOS or mortality. Antimetaboliteacic and Cardiovascular Surgery c Volume 135, Number 3 599
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tivariate model, because it is a confounding variable. Because
of the strong correlation between the use of MMF and dacli-
zumab, however, the two variables (induction and mainte-
nance immunosuppression) could not be put into the model
together, as this would render the model statistically invalid.
Analysis of antimetabolite agent within each induction group
did not show any correlation with AR. This subgroup analysis
was limited by type II error because of the small sample sizes
of 5 patients in maintenance immunosuppression groups. It is
possible that with larger sample sizes, maintenance immuno-
suppression might correlate with all three outcomes. Patients
undergoing double-lung transplantation have been shown to
have a survival advantage relative to patients undergoing
single-lung transplantation.2 Even though there were signifi-
cantly more patients undergoing bilateral lung transplantation
in the daclizumab group in our study, there was no correlation
between double-lung transplantation and the three outcomes
according to bivariate analysis. Other clinically important
variables were therefore selected for the multivariate model.
Data from ISHLT has demonstrated higher mortality after
lung transplantation to be associated with donor age, recipient
age, CMV mismatch, and diagnosis.2
Our study has several limitations. First, it is a retrospective,
single-institution study with inherent biases. Our two patient
populations were similar, however, with respect to baseline
characteristics and intraoperative data (Table 1). Second,
there were notable differences in maintenance immunosup-
pression during our two study periods. There are conflicting
data regarding the effects of specific maintenance regimens
on outcomes. In a recent multicenter randomized trial, azathi-
oprine and MMF did not differ with respect to the develop-
ment of AR or BOS or to survival at 3 years.17 Previous
studies have compared tacrolimus and cyclosporine in the
treatment of AR and BOS. A retrospective review demon-
strated that tacrolimus was superior to cyclosporine for
patients with AR or BOS.18 In contrast, a prospective, ran-
domized study demonstrated no differences in associated
BOS or survival between tacrolimus and cyclosporine.19
Several multicollinear variables were evaluated in our study.
Daclizumab was used most often in conjunction with MMF
during a more mature era of our lung transplant program.
These variables are difficult to separate because of their col-
linearity and also the limited sample size. It is likely that some
of the effects seen on these three outcomes are due to con-
comitant effects daclizumab and MMF. Third, although we
did not find any differences in the selection, intraoperative
management, or postoperative care of these transplant recip-
ients with time, our lung transplant program has matured,
with greater experience of our lung transplant surgeons and
pulmonologists and greater use of bilateral lung transplanta-
tion. Collectively, the improved evolution of our program
may have contributed to our improved outcomes in patients
who received daclizumab. The ISHLT Registry has reported600 The Journal of Thoracic and Cardiovascular Surgery c Maan improvement in survival in recent transplant recipients
relative to earlier eras.2 As such, the improved survival in
the later group with the use of daclizumab induction may
also be related to improvements in processes of care. Fourth,
our median follow-up of 1.8 years in the daclizumab group
was short. With longer follow-up, it is possible that the ben-
efits seen after daclizumab induction may be lost. Finally, the
seven daily AT doses used in our study differ from previous
reports. Burton and colleagues8 administered AT at 12.5 mg/
(kg $ d) for three doses, whereas the protocol used by Brock
and associates7 included a 7-day course of AT starting at 15
mg/(kg $ d) and adjusted daily. Neither report documented
the number of patients who received all intended doses. Dif-
ferences in our AT protocol relative to other studies may in
part explain our outcomes.
PTLD has been linked to the use of induction agents after
renal transplantation.20 In one study, an IL-2R inhibitor as an
induction agent was not associated with any increase in
PTLD relative to no induction, whereas use of AT induction
was associated with a 55% increase in PTLD.20 Because of
the relatively low incidence of any type of malignancy in
our study, we did not document differences in malignancy
after either induction agent.
In conclusion, AR and BOS were improved in patients
receiving daclizumab induction immunosuppression relative
to AT. In addition, there was a trend toward improved sur-
vival among patients receiving daclizumab. Poor tolerance
to AT resulted in fewer patients completing the induction
protocol. Differences in maintenance immunosuppression
during the two different periods, as well as improvements
in the evolution of care of our maturing lung transplant pro-
gram, may also explain these outcomes. This study supports
the need for prospective, randomized trials comparing induc-
tion agents in lung transplantation.
We thank Bev Ryan and Donna Charlebois, our Lung Transplant
Coordinators, for data extraction.
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Discussion
Dr Yoshiya Toyoda (Pittsburgh, Pa). What do you think is the
mechanism of the difference in outcome between daclizumab and
AT, because previously we have shown there is no difference in
AR and survival between daclizumab and AT, and alemtuzumab
induction is much better in terms of AR. Are there any differencesThe Journal of Thorin, for example, pulmonary protection or preservation protocols
for infection, prophylaxis, or ventilatory management?
Dr Ailawadi. Those are good questions. The question is basi-
cally to try to elucidate why we saw these differences between the
AT group and the daclizumab group. Primarily, what we saw with
our patients receiving AT was that they got very sick, and few pa-
tients were able to tolerate the full course of AT induction. Patients
receiving daclizumab were all able to tolerate the full treatment
courses, as long as they survived, as most of them did.
As to why AR, BOS, and survival would all have similar out-
comes dependent on induction, what we see is that of all patients
who had AR, 46% went on to have BOS, and approximately 42%
of patients that had BOS died during the study period. So these three
outcomes are clearly linked. Our hope is that if we can prevent the
first insult, AR, we may be able to interfere with later outcomes.
Dr Toyoda. Have you checked T-cell or B-cell counts to, for
example, 6 months? With alemtuzumab induction, those are signif-
icantly less. That can explain this AR.
Dr Ailawadi. We do not routinely check T or B cell counts.
Dr Toyoda. Then you changed your lung preservation or protec-
tion protocol?
DrAilawadi. There were no differences. We used the same pres-
ervation agent during the study period.
Dr Mark J. Krasna (Towson, Md). Just to follow up that last
question, during this long period, were there any other changes in
technique? Obviously, you talked about the maturation of the pro-
gram. I assume that if you looked at the number of cases per year,
it probably increased in the later years. Were there any changes in
technique that might have had significance?
Dr Ailawadi. We really looked hard for any differences, and we
did not find anything concrete that was different. Our volumes
increased slightly during the study period, ranging from 16 trans-
plants per year in the AT era to 20 transplants per year in the dacli-
zumab era.
Dr Bansi Koul (Lund, Sweden). I was wondering about these
two series conducted over time. How about patients with, say,
HLA antibodies? How are you managing those patients, or did
you exclude those from this study?
DrAilawadi.We routinely used these induction agents in all our
patients. So we did not exclude any patients because of HLA anti-
bodies.
Dr Koul. So you are confident in using daclizumab for patients
who have a high percentage of antibodies in the blood, without any
monitoring for them in the early postoperative period?
Dr Ailawadi. We monitor them for clinical outcomes. We used
daclizumab for all patients, even those with high antibody levels.
Shu S. Lin (Durham, NC). I congratulate you for presenting
such a clear study. I do have one question; during your analysis
did you find any difference in the number of biopsies obtained in
the two eras?
Dr Ailawadi. That is a good question. We have not looked at
that, and it would be interesting to know the number of patients
who underwent diagnosis by various criteria, whether pathologic
or clinical criteria.
DrKrasna. Just one other question perhaps you could clarify for
us. You obviously have some ideas about why you see the difference
in AR in those patients with chronic obstructive pulmonary disease,
something that you have never heard before, or why this is only theacic and Cardiovascular Surgery c Volume 135, Number 3 601
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ETsecond time we have heard a relationship with sarcoid and BOS. Do
you want to give us a supposition on your part or what your impres-
sion is?
Dr Ailawadi. As for the chronic obstructive pulmonary disease,
I don’t have a good explanation. With regard to the sarcoid, it obvi-
ously is a different disease process, and there is probably some auto-
immune process going on. The study to which I referred is actually out602 The Journal of Thoracic and Cardiovascular Surgery c Maof Pittsburgh in 1999. It studied a very small group of patients and, as
a matter of fact, didn’t reach statistical significance, but patients who
underwent transplantation for sarcoid had an incidence of BOS of
50%, significantly greater than their experience with other diagnoses.
Dr Gus J. Vlahakes (Boston, Ma). In what model is the daclizu-
mab produced? How is it made? Is it made in a murine model?
Dr Ailawadi. It is a recombinant antibody.rch 2008
